Gerstung, M. et al. The evolutionary historical past of two,658 cancers. Nature 578, 122–128 (2020).
Andor, N. et al. Pan-cancer evaluation of the extent and penalties of intratumor heterogeneity. Nat. Med. 22, 105–113 (2016).
Yates, L. R. et al. Subclonal diversification of major breast most cancers revealed by multiregion sequencing. Nat. Med. 21, 751–759 (2015).
Greaves, M. & Maley, C. C. Clonal evolution in most cancers. Nature 481, 306–313 (2012).
McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: previous, current, and the longer term. Cell 168, 613–628 (2017).
Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23–28 (1976).
Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity throughout 2,658 human most cancers genomes. Cell 184, 2239–2254.e39 (2021).
Nik-Zainal, S. et al. The life historical past of 21 breast cancers. Cell 149, 994–1007 (2012).
Gaglia, G. et al. Temporal and spatial topography of cell proliferation in most cancers. Nat. Cell Biol. 24, 316–326 (2022).
Risom, T. et al. Transition to invasive breast most cancers is related to progressive adjustments within the construction and composition of tumor stroma. Cell 185, 299–310.e18 (2022).
Dhainaut, M. et al. Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell 185, 1223–1239.e20 (2022).
Yates, L. R. et al. Genomic evolution of breast most cancers metastasis and relapse. Most cancers Cell 32, 169–184.e7 (2017).
Maley, C. C. et al. Genetic clonal variety predicts development to esophageal adenocarcinoma. Nat. Genet. 38, 468–473 (2006).
Jamal-Hanjani, M. et al. Monitoring the evolution of non–small-cell lung most cancers. N. Engl. J. Med. 376, 2109–2121 (2017).
Janiszewska, M. et al. Subclonal cooperation drives metastasis by modulating native and systemic immune microenvironments. Nat. Cell Biol. 21, 879–888 (2019).
Juric, D. et al. Convergent lack of PTEN results in scientific resistance to a PI(3)Kα inhibitor. Nature 518, 240–244 (2015).
Jones, S. et al. Comparative lesion sequencing offers insights into tumor evolution. Proc. Natl Acad. Sci. USA 105, 4283–4288 (2008).
Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide decision. Nature 461, 809–813 (2009).
Casasent, A. Okay. et al. Multiclonal invasion in breast tumors recognized by topographic single cell sequencing. Cell 172, 205–217.e12 (2018).
Tarabichi, M. et al. A sensible information to most cancers subclonal reconstruction from DNA sequencing. Nat. Strategies 18, 144–155 (2021).
Shen, C. Y. et al. Genome-wide seek for lack of heterozygosity utilizing laser seize microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast most cancers pathogenesis. Most cancers Res. 60, 3884–3892 (2000).
Zhao, T. et al. Spatial genomics allows multi-modal research of clonal heterogeneity in tissues. Nature 601, 85–91 (2022).
Erickson, A. et al. Spatially resolved clonal copy quantity alterations in benign and malignant tissue. Nature 608, 360–367 (2022).
Janiszewska, M. et al. In situ single-cell evaluation identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast most cancers. Nat. Genet. 47, 1212–1219 (2015).
Larsson, C., Grundberg, I., Söderberg, O. & Nilsson, M. In situ detection and genotyping of particular person mRNA molecules. Nat. Strategies 7, 395–397 (2010).
Grundberg, I. et al. In situ mutation detection and visualization of intratumor heterogeneity for most cancers analysis and diagnostics. Oncotarget 4, 2407–2418 (2013).
Ke, R. et al. In situ sequencing for RNA evaluation in preserved tissue and cells. Nat. Strategies 10, 857–860 (2013).
Baker, A.-M. et al. Strong RNA-based in situ mutation detection delineates colorectal most cancers subclonal evolution. Nat. Commun. 8, 1998 (2017).
Cowell, C. F. et al. Development from ductal carcinoma in situ to invasive breast most cancers: revisited. Mol. Oncol. 7, 859–869 (2013).
Svedlund, J. et al. Era of in situ sequencing primarily based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast most cancers. EBioMedicine 48, 212–223 (2019).
Wu, S. Z. et al. A single-cell and spatially resolved atlas of human breast cancers. Nat. Genet. 53, 1334–1347 (2021).
Ellis, P. et al. Dependable detection of somatic mutations in strong tissues by laser-capture microdissection and low-input DNA sequencing. Nat. Protoc. 16, 841–871 (2021).
Gataric, M. et al. PoSTcode: probabilistic image-based spatial transcriptomics decoder. Preprint at https://doi.org/10.1101/2021.10.12.464086 (2021).
Nirmal, A. J. et al. The spatial panorama of development and immunoediting in major melanoma at single-cell decision. Most cancers Discov. 12, 1518–1541 (2022).
Kole, A. J. et al. Total survival is improved when DCIS accompanies invasive breast most cancers. Sci. Rep. 9, 9934 (2019).
Going, J. J. & Moffat, D. F. Escaping from flatland: scientific and organic facets of human mammary duct anatomy in three dimensions. J. Pathol. 203, 538–544 (2004).
Schnitt, S. J. & Collins, L. C. Biopsy Interpretation of the Breast (Lippincott Williams & Wilkins, 2009).
Pinder, S. E. Ductal carcinoma in situ (DCIS): pathological options, differential prognosis, prognostic elements and specimen analysis. Mod. Pathol. 23, S8–S13 (2010).
Thomson, J. Z. et al. Progress sample of ductal carcinoma in situ (DCIS): a retrospective evaluation primarily based on mammographic findings. Br. J. Most cancers 85, 225–227 (2001).
Solin, L. J. et al. A multigene expression assay to foretell native recurrence threat for ductal carcinoma in situ of the breast. J. Natl Most cancers Inst. 105, 701–710 (2013).
Jatoi, I., Hilsenbeck, S. G., Clark, G. M. & Osborne, C. Okay. Significance of axillary lymph node metastasis in major breast most cancers. J. Clin. Oncol. 17, 2334–2340 (1999)
Sereesongsaeng, N., McDowell, S. H., Burrows, J. F., Scott, C. J. & Burden, R. E. Cathepsin V suppresses GATA3 protein expression in luminal A breast most cancers. Breast Most cancers Res. 22, 139 (2020).
Kwon, M. J. et al. CD24 overexpression is related to poor prognosis in luminal A and triple-negative breast most cancers. PLoS ONE 10, e0139112 (2015).
Li, X.-P. et al. Co-expression of CXCL8 and HIF-1α is related to metastasis and poor prognosis in hepatocellular carcinoma. Oncotarget 6, 22880–22889 (2015).
Cairns, R. A. & Hill, R. P. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine mannequin of human cervical carcinoma. Most cancers Res. 64, 2054–2061 (2004).
Sottoriva, A. et al. A Large Bang mannequin of human colorectal tumor development. Nat. Genet. 47, 209–216 (2015).
Vickovic, S. et al. Excessive-definition spatial transcriptomics for in situ tissue profiling. Nat. Strategies 16, 987–990 (2019).
Gyllborg, D. et al. Hybridization-based in situ sequencing (HybISS) for spatially resolved transcriptomics in human and mouse mind tissue. Nucleic Acids Res. 48, e112 (2020).
Lee, H., Marco Salas, S., Gyllborg, D. & Nilsson, M. Direct RNA focused in situ sequencing for transcriptomic profiling in tissue. Sci. Rep. 12, 7976 (2022).
Dobzhansky, T. Nothing in biology is sensible besides within the gentle of evolution. Am. Biol. Educate. 35, 125–129 (1973).